MS/Neuroimmunology
Clinical Research
If you think you may qualify for one of these studies, please contact Neurology Research at (303) 724-4644 or NeuroResearch@CUAnschutz.edu
| COMIRB # | Title | Principal Investigator | Eligibility and Information | Advertisement |
|---|---|---|---|---|
| Relapsing Remitting MS | ||||
20-1569 | A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of ANK-700 in Patients with Relapsing-Remitting Multiple Sclerosis | |||
20-0705 | A Single-Arm, Prospective, Multicentre, Open-Label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients with Relapsing Multiple Sclerosis Transitioning from Dimethyl Fumarate or Fingolimod Therapy (ARTIOS) | n/a | ||
19-1621 | Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) | |||
| 20-3026 | A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis (FENhance) | Enrique Alvarez, MD, PhD | Clinical Trials | See Advertisement |
| 20-1101 | A Phase 3, Randomized, Double-Blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants with Relapsing Forms of MS (GEMINI I) | Enrique Alvarez, MD, PhD | Clinical Trials | See Advertisement |
| 20-1047 | A Phase 3, Randomized, Double-Blind Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants with Non Relapsing Secondary Progressive MS (HERCULES) | Enrique Alvarez, MD, PhD | Clinical Trials | See Advertisement |
| 19-2420 | A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (Rpc-1063) | Amanda Piquet, MD | Clinical Trials | n/a |
20-2135 | A Single-Arm, Prospective, Multi-Center, Study to Explore Maintained Efficacy with Ofatumumab Therapy in Patients with Relapsing Multiple Sclerosis who Discontinue Intravenously Delivered Anti-CD20 Monoclonal Antibody (aCD20 mAb) Therapy (OLIKOS) | n/a | ||
| Primary Progressive MS | ||||
20-0454 | A Phase 1, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study with an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects with Progressive Multiple Sclerosis | n/a | ||
| 21-2663 | A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrevus in Adult Patients with Primary Progressive MS (FENtrepid) | Enrique Alvarez, MD, PhD | Clinical Trials | n/a |
| 20-1100 | A Phase 3, Randomized, Double-Blind Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants with Primary Progressive MS (PERSEUS) | Enrique Alvarez, MD, PhD | Clinical Trials | Clinical Trials |
| 20-1853 | A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Primary Progressive MS (Gavotte) | Enrique Alvarez, MD, PhD | Clinical Trials | See Advertisement |
| Newly Diagnosed MS | ||||
18-1633 | Determining the Effectiveness of Early Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS) | n/a | ||
| 20-1000 | Central Vein Sign: A Diagnostic Biomarker in MS (CAVS-MS) | Enrique Alvarez, MD, PhD | Clinical Trials | n/a |
| Healthy Volunteers | ||||
17-1884 | Risk Factors in Early Multiple Sclerosis (RISE-MS) | |||
19-0393 | Detection and Risk in Early MS (DREAMS) | n/a | ||
| Exercise Studies | ||||
20-0695 | Low Load Resistance Training Using Blood Flow Restriction for People with Multiple Sclerosis with Marked Mobility Restriction | |||
18-0179 | Comparative Effectiveness of an Exercise Intervention Delivered via Telerehabilitation and Conventional Mode of Delivery | |||
20-1527 | Proximal Resistance Training to Improve Walking Capacity and Physical Activity in People with Multiple Sclerosis | |||
| Bio and Tissue Banks | ||||
12-0968 | Rocky Mountain Multiple Sclerosis Center (RMMSC) Biorepository for the Study of Neuroimmunological Disorders | n/a | ||
09-0952 | Rocky Mountain MS Center Tissue Bank | n/a | ||